Cagrilintide Overview
Category:
Long-acting amylin analogue (peptide)
How it works:
Agonist at amylin and related calcitonin family receptors in the brainstem; reduces hunger, slows gastric emptying, and suppresses post-meal glucagon — producing reduced caloric intake and improved post-prandial glucose handling
Alternative names / combos:
Cagrilintide alone; combined with semaglutide marketed in trials as “CagriSema” or cagrilintide-semaglutide
Primary research focus:
- Obesity and weight management;
- Adjunctive use in type 2 diabetes and cardiometabolic endpoints when combined with GLP-1 therapy
Potential risks:
Gastrointestinal tolerability (nausea, vomiting, diarrhea/constipation), injection-site reactions, limited long-term human safety data; possible interactions when used with other glucose-lowering drugs
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analogue of amylin — a hormone co-secreted with insulin from pancreatic β-cells that contributes to satiety and slows gastric emptying. It was engineered for once-weekly subcutaneous dosing to provide sustained appetite suppression and metabolic effects useful in overweight or obesity. Research programs have tested cagrilintide by itself and in combination with semaglutide (a GLP-1 receptor agonist) to amplify weight-loss effects.
How it works in the body
Cagrilintide acts primarily via amylin receptors in the hindbrain and related calcitonin receptor complexes. Its main physiological effects are:
- Satiety enhancement: decreases meal size and frequency by signaling fullness.
- Delayed gastric emptying: prolongs gastric retention of food, which supports reduced intake.
- Glucagon suppression and post-prandial glucose control: helps blunt spikes in blood glucose when used alone or with GLP-1 therapy.
When combined with a GLP-1 (semaglutide), the two agents produce complementary effects — the GLP-1 reduces appetite and improves insulin secretion, while cagrilintide adds stronger meal-termination and satiation signals — producing larger weight loss than either alone in trials.
Cagrilintide Benefits
1. Meaningful weight loss (especially in combination)
Clinical data show cagrilintide produces clinically relevant weight loss, and the combination cagrilintide+semaglutide (often called CagriSema) typically produced greater weight reductions than semaglutide alone in randomized trials. That synergistic effect is why combination development is a major focus.
2. Once-weekly convenience
Unlike native amylin (which requires frequent dosing), cagrilintide was designed for once-weekly injection, improving adherence potential.
3. Reduced caloric intake via stronger satiety
By acting on amylin pathways, cagrilintide reduces meal size and frequency, which translates into net calorie reduction over time.
4. Improved glycemic markers when appropriate
Trials in people with type 2 diabetes evaluated the combination with semaglutide and found improved weight and glycemic outcomes versus controls, indicating utility in metabolic disease when used under medical supervision.
5. Potential cardiometabolic benefits (emerging)
Recent large studies of the cagrilintide+semaglutide program reported additional benefits (e.g., systolic blood pressure reductions and inflammatory marker improvements), which are being followed up in cardiovascular outcome studies.
Clinical studies
- Dose-finding Phase 2 (Lancet, 2021): A multicenter randomized dose-finding trial showed dose-dependent weight loss with once-weekly cagrilintide and characterized tolerability.
- Co-administered cagrilintide + semaglutide (NEJM / 2025): A phase 2 trial reported substantial additional weight loss with co-administration (example headline numbers: trials reported high single-digit to low-double-digit percent body-weight reductions over 26–68 weeks, depending on dose and regimen).
- REDEFINE & later trials (Phase 3 program CagriSema): Large trials of the combination vs semaglutide alone and vs placebo have been run and reported mixed but generally positive results; regulatory and cardiovascular outcome trials are underway or planned to confirm safety and long-term benefit. Recent press releases and conference data highlighted blood-pressure and inflammatory marker improvements in addition to weight loss.
- Ongoing/registered trials: Multiple studies are listed on ClinicalTrials.gov exploring cagrilintide alone, in combination with semaglutide, different doses, and specific populations (e.g., people with type 2 diabetes; pediatric plans for the combination are being initiated).
Safety, side effects, and considerations
Common adverse events: Gastrointestinal symptoms dominate (nausea, vomiting, diarrhea, constipation), particularly during dose escalation — these are similar to GLP-1 agents and other appetite-suppressing therapies. Injection-site reactions and transient headache/fatigue are also reported. Tolerability influences how many patients escalate to higher target doses.
Serious safety signals: To date, published trials and trial reports have not revealed new major safety crises, but longer-term and larger cardiovascular outcome data are still being collected. Because cagrilintide affects appetite and gastric emptying, there are theoretical concerns when used with other glucose-lowering drugs (risk of hypoglycemia) or in patients with certain GI disorders — these must be managed clinically.
Who should avoid / special populations: Pregnant or breastfeeding people, those with a history of medullary thyroid carcinoma (class precaution for many weight-loss peptide drugs), or severe GI disease should not use such investigational peptides outside of a clinical trial. Always follow prescriber guidance and regulatory approvals where available. (Cagrilintide is investigational — not FDA-approved for general use as of the latest trial reports.)
Bottom line
Cagrilintide is a promising long-acting amylin analogue developed to support weight loss and metabolic control, especially when combined with a GLP-1 (semaglutide) — the combination (“CagriSema”) has produced greater weight loss than semaglutide alone in multiple trials. Gastrointestinal tolerability and the need for longer-term safety and cardiovascular outcome data remain the principal open questions. If you’re researching therapeutic options or planning patient counseling, focus on the trial evidence, tolerability strategies (slow titration), and that the drug is investigational until regulatory approvals are finalized.
